revumenib

a menin inhibitor

Also Known As:

N-ethyl-2-(4-(7-((4-(ethylsulfonylamino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)nonan-2-yl)pyrimidin-5-yl)oxy-5-fluoro-N-propan-2-ylbenzamide

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

1.	Leukemia 01/01/2023 - "Revumenib Appears Safe in Leukemia Trial, Yields Remission in Some." 08/01/2023 - "Revumenib treatment blocks leukemic engraftment and prevents leukemia-associated death of immunodeficient mice transplanted with NUP98::NSD1 FLT3-ITD-positive patient-derived AML cells. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2023 - "Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar."

1.	nuclear pore complex protein 98